- Home
- ALLO vs BUI Comparison
ALLO vs BUI Comparison
Compare ALLO & BUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | BUI |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.1M | 692.8M |
| IPO Year | 2018 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ALLO | BUI |
|---|---|---|
| Price | $2.02 | $26.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $8.35 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 69.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $24.85 |
| 52 Week High | $4.46 | $30.80 |
Technical Indicators
Market Signals| Indicator | ALLO | BUI |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 47.86 |
| Support Level | $1.87 | $27.15 |
| Resistance Level | $2.25 | $27.47 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 38.71 | 49.11 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About BUI BlackRock Utility Infrastructure & Power Opportunities Trust
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure, and Power Opportunities business segments anywhere in the world and by employing writing (selling) call and put options.